Evolution Biotechnologies | 2019 January
0
archive,date,ajax_fade,page_not_loaded,,qode-title-hidden,qode-theme-ver-16.4,qode-theme-bridge,wpb-js-composer js-comp-ver-5.4.7,vc_responsive

Bedford, UK, January 9th, 2019 Evolution Biotechnologies (www.evolutionbiotech.com), the UK and US-based company pioneering the use of biological control to benefit human health, today reports an interview with CEO Dr. David Harper, conducted by media company Proactive Investors during Biotech Showcase 2019. The interview covered the background to Evolution’s development of a novel, self-replicating control technology for house dust mites. Also covered were the recent granting of a European patent for this approach, and the company’s development plans. Dr. David Harper, Evolution’s CEO, said: “It is good to have the opportunity to speak to a wider audience about Evolution’s exciting developments in this...

Bedford, UK, January 9th, 2019 Evolution (www.evolutionbiotech.com), the UK and US-based company pioneering the use of biological control to benefit human health, today reports the announcement by the European Patent Office of notification of intention to grant Evolution’s patent EP3331366, “Acaricides”. The patent protects Evolution’s lead technology, developing a biological control for the house dust mite as a preventative for asthma. The patent provides broad protection for any use of replicating biological agents for the control of house dust mites (HDM). The first claim protects “A method of treating or preventing a house dust mite infestation, said method comprising applying an...

Bedford, UK, October 3rd 2018 Evolution Biotechnologies (www.evolutionbiotech.com), the UK and US-based company pioneering the use of biological control to benefit human health, today announced its intention to present at the Biotech Showcase in San Francisco. CEO Dr. David Harper will present a summary of the company’s activities, along with news of a major development on its key asthma control technology. About Evolution Biotechnologies Evolution Biotechnologies (UK company 09473027 and US company 6050853) is working to extend the application of biological control from its proven efficacy in agriculture into biomedical markets. The company’s initial target is the development of a novel, self-amplifying biological...